denufosol tetrasodium (INS37217)
Phase 2Small molecule
Merck & Co.denufosol tetrasodium (INS37217) is one of 119 small molecule programs targeting Retinal Detachment. It is currently in Phase 2.
5
Indications
15
Total Trials
0
Active Trials
118
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1denufosol tetrasodium (INS37217)
Merck & Co.Phase 2
Onglyza
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Aztreonam Lysine
GileadPreclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cystic Fibrosis8 trials
Show 5 more trials
Cataract1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company